Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder ...

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.